Seminars in Hematology
Volume 44, Issue 3 , Pages 166-182 , July 2007

Cytokines for the Treatment of Thrombocytopenia

  • Stefan O. Ciurea

      Affiliations

    • University of Illinois at Chicago College of Medicine, Chicago, IL.
    • Myeloproliferative Diseases Research Consortium, New York, NY.
    • ,
  • Ronald Hoffman

      Affiliations

    • University of Illinois at Chicago College of Medicine, Chicago, IL.
    • Myeloproliferative Diseases Research Consortium, New York, NY.
    • Corresponding Author InformationAddress correspondence to Ronald Hoffman, MD, Hematology/Oncology Section, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, New York, NY 10029.

References 

  1. Ganser A, Hoelzer D. Cytokines in the Treatment of Hematopoietic Failure. New York, NY: Marcel Dekker; 1999;
  2. Akashi K, Traver D, Miyamoto T, Weissman IL. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature. 2000;404:193–197
  3. Adolfsson J, Mansson R, Buza-Vidas N, Hultquist A, Liuba K, Jense CT, et al. Identification of Flt3+ lympho-myeloid stem cells lacking erythro-megakaryocytic potential: A revised road map for adult blood lineage commitment. Cell. 2005;121:295–306
  4. Long MW, Gragowski LL, Heffner CH, Boxer LA. Phorbol diesters stimulate the development of an early murine progenitor cell (The burst-forming unit-megakaryocyte). J Clin Invest. 1985;76:431–438
  5. Briddell RA, Brandt JE, Straneva JE, Srour EF, Hoffman R. Characterization of the human burst-forming unit-megakaryocyte. Blood. 1989;74:145–151
  6. Deutsch VR, Tomer A. Megakaryocyte development and platelet production. Br J Haematol. 2006;134:453–466
  7. Tomer A, Harker LA, Burstein SA. Flow cytometric analysis of human megakaryocytes. Blood. 1988;71:1244–1252
  8. Levine RF. Isolation and characterization of normal human megakaryocytes. Br J Haematol. 1980;45:487–497
  9. Williams N, Levine RF. The origin, development and regulation of megakaryocytes. Br J Haematol. 1982;52:173–180
  10. Gewirtz AM. Human megakaryocytopoiesis. Semin Hematol. 1986;23:27–42
  11. Patel S, Hartwig JH, Italiano JE. The biogenesis of platelets from megakaryocyte proplatelets. J Clin Invest. 2005;115:3348–3362
  12. Hartwig JH. The platelet: Form and function. Semin Hematol. 2006;43(suppl 1):S94–S100
  13. Schulze H, Shivdasani RA. Mechanisms of thrombopoiesis. J Thromb Haemost. 2005;3:17171–1724
  14. Zauli G, Vitale M, Falcieri E, et al. In vitro senescence and apoptotic cell death of human megakaryocytes. Blood. 1997;90:2234–2243
  15. De Botton S, Sabri S, Daugas E, Zermati Y, Guidotti JE, Hermine O, et al. Platelet formation is the consequence of caspase activation within megakaryocytes. Blood. 2002;100:1310–1317
  16. Kaluzhny Y, Ravid K. Role of apoptotic process in platelet biogenesis. Acta Haematol. 2004;111:67–77
  17. Kaluzhny Y, Yu G, Sun S, Toselli PA, Nieswandt B, Jackson CW, et al. BclxL overexpression in megakaryocytes leads to impaired platelet fragmentation. Blood. 2002;100:1670–1678
  18. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996;87:2095–2147
  19. Williams DE, Morrissey PJ. Alterations in megakaryocyte and platelet compartments following in vivo IL-1 beta administration to normal mice. J Immunol. 1989;142:4361–4365
  20. Kimura H, Ishibashi T, Shikama Y, Okano A, Akiyama Y, Uchida T, et al. Interleukin-1 beta (IL-1 beta) induces thrombocytosis in mice: Possible implications of IL-6. Blood. 1990;76:2493–2500
  21. Monroy RL, Davis TA, Donahue RE, MacVittie TJ. In vivo stimulation of platelet production in a primate model using IL-1 and IL-3. Exp Hematol. 1991;19:629–635
  22. Hapel AJ, Fung MC, Johnson RM, Young IG, Johnson G, Metcalf D. Biologic properties of molecularly cloned and expressed murine interleukin-3. Blood. 1985;65:1453–1459
  23. Spivak JL, Smith RR, Ihle JN. Interleukin-3 promotes the in vitro proliferation of murine pluripotent hematopoietic stem cells. J Clin Invest. 1985;76:1613–1621
  24. Mazur EM, Cohen JL, Bogart L, Mufson RA, Gesner TG, Yang YC, et al. Recombinant globulin interleukin-3 stimulates megakaryocyte colony growth in vitro from human peripheral blood progenitor cells. J Cell Physiol. 1988;136:439–446
  25. Robinson BE, McGrath HE, Quesenberry PJ. Recombinant murine granulocte macrophage colony factor has megakaryocyte colony stimulating activity and augments megakaryocyte colony stimulation by interleukin-3. J Clin Invest. 1987;79:1648–1652
  26. Ishibashi T, Kimura H, Shikama Y, Uchida T, Kariyone S, Maruyama Y. Effect of recombinant granulocyte-macrophage colony-stimulating factor on murine thrombocytopoiesis in vitro and in vivo. Blood. 1990;75:1433–1438
  27. Leary AG, Yang Y-C, Clark SC, Gasson JC, Golde DW, Ogawa M. Recombinant gibbon interleukin 3 supports formation of human multilineage colonies and blast cell colonies in culture: comparison with recombinant human granulocyte-macrophage colony-stimulating factor. Blood. 1987;70:1343–1348
  28. Quesenberry PJ, Ihle JN, McGrath E. The effect of interleukin 3 and GM-CSA-2 on megakaryocyte and myeloid clonal colony formation. Blood. 1985;65:214–217
  29. Bruno E, Briddell R, Hoffman R. Effect of recombinant and purified hematopoietic growth factors on human megakaryocyte colony formation. Exp Hematol. 1988;16:371–377
  30. Le J, Vilcek J. Biology of disease (A multifunctional cytokine regulating immune reactions and the acute phase protein response). Lab Invest. 1989;61:588–602
  31. Ishibashi T, Kimura H, Uchida T, Kariyone S, Friese P, Burstein SA. Human interleukin 6 is a direct promoter of maturation of megakaryocytes in vitro. Proc Natl Acad Sci U S A. 1989;86:5953–5957
  32. Hill RJ, Warren MK, Levin J. Stimulation of thrombopoiesis in mice by human recombinant interleukin 6. J Clin Invest. 1990;85:1242–1247
  33. Takatsuki F, Okano A, Suzuki C, Mikyasaka Y, Hirano T, Kishimoto T, et al. Interleukin 6 perfusion stimulates reconstitution of the immune and hematopoietic systems after 5-fluorouracil treatment. Cancer Res. 1990;50:2855–2890
  34. Patchen M, MacVittie TJ, Williams JL, Schwartz GN, Souza LM. Administration of inteleukin-6 stimulates multi-lineage hematopoiesis and accelerates recovery from radiation-induced hematopoietic depression. Blood. 1991;77:472–480
  35. Ikebuchi K, Wong GC, Clark SC, Ihle JN, Hirai Y, Ogawa M, et al. Interleukin 6 enhancement of interleukin 3 dependent proliferation of multipotential hematopoietic progenitors. Proc Natl Acad Sci U S A. 1987;84:9035
  36. Bruno E, Hoffman R. Effect of inteleukin 6 on in vitro human megakaryocytopoiesis: its interaction with other cytokines. Exp Hematol. 1989;17:1038–1043
  37. Straneva JE, van Besien KW, Derigs G, Hoffman R. Is interleukin 6 the physiologic regulator of thrombocytosis?. Exp Hematol. 1992;20:47–52
  38. Kaser A, Brandacher G, Steurer W, Kaser S, Offner FA, Zoller H, et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin. Role in inflammatory thrombocytosis. 2001;98:2720–2725
  39. Goldman SJ. Preclinical biology of interleukin 11: A multifunctional hematopoietic cytokine with potent thrombotic activity. Stem Cells. 1995;13:462–471
  40. Du XX, Williams DA. Interleukin-11: Review of molecular, cell biology and clinical use. Blood. 1997;89:3897–3908
  41. Bruno E, Briddell RA, Cooper RJ, Hoffman R. Effects of recombinant interleukin 11 on human megakaryocyte progenitor cells. Exp Hematol. 1991;19:378–381
  42. Du XX, Scott D, Yang ZX, Cooper R, Xiao XL, Williams DA. Interleukin-11 stimulates multi-lineage progenitors, but not stem cells, in murine and human long-term marrow cultures. Blood. 1995;86:128
  43. Leonard JP, Neben TY, Kozitza MK, Quinto CM, Goldman SJ. Constant subcutaneous infusion of rhIL-11 in mice: efficient delivery enhances biological activity. Exp Hematol. 1996;24:270–276
  44. Fourcin M, Chevalier S, Lebrun J-J, Kelly P, Pouplard A, Wijdenes J, et al. Involvement of gp130/interleukin-6 receptor transducting component in interleukin-11 receptor. Eur J Immunol. 1994;24:277–280
  45. Yin T, Yasukawa K, Taga T, Kishimoto T, Yang YC. Identification of a 130-kilodalton tyrosine-phosphorylated protein induced by interleukin-11 as JAK2 tyrosine kinase, which associates with gp130 signal transducer. Exp Hematol. 1994;22:467–472
  46. Turner KJ, Neben S, Weich N, Schaub RG, Goldman SJ. The role of interleukin-11 in megakaryocytopoiesis. Stem Cells. 1996;14:53–61
  47. Kaushansky K. Thrombopoietin. N Engl J Med. 1998;339:746–753
  48. Deutsch VR, Tomer A. Megakaryocyte development and platelet production. Br J Haematol. 2006;134:453–466
  49. de Sauvage FJ, Hass PE, Spencer SD, Malloy BE, Gurney AL, Spencer SA, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature. 1994;369:533–538
  50. Lok S, Kaushansky K, Holly RD, Kuijper JL, Lofton-Day CE, Oort PJ, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature. 1994;369:565–568
  51. Broudy VC, Lin NL, Kaushansky K. Thrombopoietin (c-mpl ligand) acts synergistically with erythropoirtin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood. 1995;85:1719–1726
  52. Debili N, Wendling F, Katz E, Guichard J, Breton-Gorius J, Hunt P, et al. The Mpl-ligand or thrombopoietin or megakaryocyte growth and differentiative factor has both direct proliferative and differentiative activities on human megakaryocytes. Blood. 1995;86:2516–2525
  53. Campus F, Lova P, Bertoni A, Sinigaglia F, Balduini C, Torti M. Thrombopoietin complements G(i)- but not G(q)-dependent pathways for integrin{alpha}(IIb){beta}(3) activation and platelet aggregation. J Biol Chem. 2005;280:24386–24395
  54. Van Os, Wu YP, Pouwels JG, Ijsseldijk MJ, Sixma JJ, Akkerman JW, et al. Thrombopoietin increases platelet adhesion under flow and decreases rolling. Br J Haematol. 2003;121:482–490
  55. Choi ES, Hokom MM, Chen JL, Skrine J, Faust J, Nichol J, et al. The role of megakaryocyte growth and development factor in terminal stages of thrombopoiesis. Br J Haematol. 1996;95:227–233
  56. Shinjo K, Takeshita A, Nakamura S, Naitoh K, Yanagi M, Tobita T, et al. Serum thrombopoietin levels in patients correlate inversely with platelet counts during chemotherapy-induced thrombocytopenia. Leukemia. 1998;12:295–300
  57. Engel C, Leffler M, Franke H, Schmitz S. Endogenous thrombopoietin serum levels during multicycle chemotherapy. Br J Haematol. 1999;105:832–838
  58. Kaushansky K: The molecular mechanisms that control thrombopoiesis. J Clin Invest 115:3339-3347
  59. Kosugi S, Kurata Y, Tomiyama Y, Tahara T, Kato T, Tadokoro S, et al. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br J Haematol. 1996;93:704–706
  60. Ichikawa N, Ishida F, Shimodaira S, Tahara T, Kato T, Kitano K. Regulation of serum thrombopoietin levels by platelets and megakaryocytes in patients with aplastic anemia and idiopathic thrombocytopenia purpura. Thromb Haemost. 1996;76:156–160
  61. Peck-Radosavljevic M, Zacherl J, Meng YG, Pidlich J, Lipinski E, Langle F, et al. Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver?. J Hepatol. 1997;27:127–131
  62. Kajihara M, Okazaki Y, Kato S, Ishii H, Kawakami Y, Ikeda Y, et al. Evaluation of platelet kinetics in patients with liver cirrhosis:similarity to idiopathic thrombocytopenic purpura. Hapatology. 2007;22:112–118
  63. Giannini EG. Review article: Thrombocytopenia in chronic liver disease and pharmacologic treatment options. Aliment Pharmacol Ther. 2006;23:1055–1065
  64. Shivdasani RA. Molecular and transcriptional regulation of megakaryocyte differentiation. Stem Cells. 2001;19:397–407
  65. Lecine P, Villeval JL, Vyas P, Swencki B, Xu Y, Shivdasani RA. Mice lacking transcription factor NF-E2 provide in vivo validation of the proplatelet model of thrombocytopoiesis and show a platelet production defect that is intrinsic to megakaryocytes. Blood. 1998;92:1608–1616
  66. Lecine P, Italiano JE, Kim SW, Villeval JL, Shivdasani RA. Hematopoietic-specific β1 tubulin participates in a pathway of platelet biogenesis dependent on the transcription factor NF-E2. Blood. 2000;96:1366–1373
  67. McCormack MP, Hall MA, Schoenwaelder SM, Zhao Q, Ellis S, Prentice JA, et al. A critical role for the transcription factor Scl in platelet production during stress thrombopoiesis. Blood. 2006;108:2248–2256
  68. Levine RF, Eldor A, Schoff PK, Kirwin S, Tenza D, Cramer EM. Circulating megakaryocytes: Delivery of large numbers of intact, mature megakaryocytes to the lungs. Eur J Haematol. 1993;51:233–246
  69. Levine RF, Schoff P, Han ZC, Eldor A. Circulating megakaryocytes and platelet production in the lungs. Prog Clin Biol Res. 1990;356:41–52
  70. Zucker-Franklin D, Philipp CS. Platelet production in the pulmonary capillary bed: new ultrastructural evidence for an old concept. Am J Pathol. 2000;157:69–74
  71. Lane WJ, Dias S, Hattori K, Heissig B, Choy M, Rabbany SY, et al. Stromal-derived factor1-induced megakaryocyte migration and platelet production is dependent on matrix metalloproteinases. Blood. 2000;96:4152–4159
  72. Avecilla ST, Hattori K, Heissig B, Tejada R, Liao F, Shido K, et al. Chemokine-mediated interactions of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med. 2004;10:64–71
  73. Tewari A, Buhles WC, Starnes HF. Preliminary report: Effects of interleukin-1 on platelet counts. Lancet. 1990;336:712–714
  74. Crown J, Jakubowski A, Kemeny N, Gordon M, Gasparetto C, Wong G, et al. A phase I trial of recombinant human interleukin-1β alone and in combination with myelosupressive doses of 5-fluorouracil in patients with gastrointestinal cancer. Blood. 1991;78:1420–1427
  75. Smith JW, Longo DL, Alvord WG, Janik JE, Sharfman WH, Gause BL, et al. The effects of treatment with interleukin-1α on platelet recovery after high-dose carboplatin. N Engl J Med. 1993;328:756–761
  76. Vadhan-Raj S, Kudelka AP, Garrison L, Gano J, Edwards CL, Freedman RS, et al. Effects of interleukin-1α on carboplatin-induced thrombocytopenia in patients with recurrent ovarian cancer. J Clin Oncol. 1994;12:707–714
  77. Ganser A, Lindemann A, Seipelt G, Ottman OG, Hermann F, Eder M, et al. Effects of recombinant human interleukin-3 in patients with normal hematopoiesis and in patients with bone marrow failure. Blood. 1990;76:666–676
  78. Biesma B, Willemse PH, Mulder NH, Sleijfer DT, Gietema JA, Mull R, et al. Effects of interleukin-3 after chemotherapy for advanced ovarian cancer. Blood. 1992;80:1141–1148
  79. D’Hondt V, Weynants P, Humblet Y, Guillaume T, Canon JL, Beauduin M, et al. Dose-dependent interleukin-3 stimulation of thrombopoiesis and neutropoiesis in patients with small-cell lung carcinoma before and following chemotherapy: A placebo-controlled randomized phase Ib study. J Clin Oncol. 1993;11:2063–2071
  80. Veldhuis GJ, Willemse PH, van Gameren MM, Veldhuis GJ, Willemse PH, van Gameren MM, et al. Recombinant human interleukin-3 to dose-intensity carboplatin and cyclophosphamide chemotherapy in epithelial ovarian cancer: A phase I trial. J Clin Oncol. 1995;13:733–740
  81. Kudoh S, Sawa T, Kurihara N, Furuse K, Kurita Y, Fukuoka M, et al. Phase II study of recombinant human interleukin 3 administration following carboplatin and etoposide chemotherapy in small-cell lung cancer patients (SDZ ILE 964 (IL-3) study). Cancer Chemother Pharmacol. 1996;38(suppl):S89–S95
  82. Yamamoto K, Yajima A, Terashima Y, Nozawa S, Taketani Y, Yakushiji M, et al. SDZ ILE 964 (IL-3) Study Group Phase II clinical study on the effects of recombinant human interleukin-3 on thrombocytopenia after chemotherapy for advanced ovarian cancer. J Immunother. 1999;22:539–545
  83. Tepler I, Elias A, Kalish L, Shulman L, Strauss G, Skarin A, et al. Effect of recombinant human interleukin-3 on hematological recovery from chemotherapy-induced myelosupression. Br J Haematol. 1994;87:678–686
  84. Ganser A, Seipelt G, Lindemann A, Ottmann OG, Falk S, Eder M, et al. Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes. Blood. 1990;76:455–462
  85. Ganser A, Lindemann A, Seipelt G, Ottmann OG, Eder M, Falk S, et al. Effects of recombinant human interleukin-3 in aplastic anemia. Blood. 1990;76:1287–1292
  86. Barnstein SH, Fay JP, Christiansen NP, Pinero L, Shah D, Stephan M, et al. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial. Clin Cancer Res. 1997;3:1519–1526
  87. Nand S, Sosman J, Godwin JE, Fisher RI. A phase I/II study of sequential interleukin-3 and granulocyte-macrophage colony-stimulating factor in myelodysplastic syndromes. Blood. 1994;83:357–360
  88. Vadhan-Raj S, Papadopoulos NE, Burgess MA, Linke KA, Patel SR, Hays C, et al. Effects of PIXY321, a granulocyte-macrophage colony stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosupression in patients with sarcoma. J Clin Oncol. 1994;12:715–724
  89. Runowicz CD, Mandeli J, Speyer JL, Wadler S, Hochster H, Garrison L, et al. Phase I/II study of PIXY321 in combination with cyclophosphamide and carboplatin in the treatment of ovarian cancer. Am J Obstet Gynecol. 1996;174:1151–1159
  90. Jones SE, Khandelwal P, McIntyre K, Mennel R, Orr D, Kirby R, et al. Randomized, double-blond, placebo-controlled trial to evaluate the hematopoietic growth factor PIXY321 after moderate-dose fluorouracil, doxorubicin, and cyclophosphamide in stage II and III breast cancer. J Clin Oncol. 1999;17:3025–3032
  91. Miller LL, Korn EL, Stevens DS, Janik JE, Gause BL, Kopp WC, et al. Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin. Blood. 1999;93:3250–3258
  92. van Gameren MM, Willemse PHB, Mulder NH, Limburg PC, Groen HJ, Vellenga E, et al. Effects of recombinant human IL-6 in cancer patients: a phase I-II study. Blood. 1994;84:1434–1441
  93. Veldhuis GJ, Willemse PHB, Sleijfer DT, van der Graaf WT, Groen HJ, Limburg PC, et al. Toxicity and efficacy of escalating doses of recombinant human interleukin-6 after chemotherapy in patients with breast cancer of non-small-cell lung cancer. J Clin Oncol. 1995;13:2585–2593
  94. Gordon MS, Nemunaitis J, Hoffman R, Paquette RL, Rosenfeld C, Manfreda S, et al. A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia. Blood. 1995;85:3066–3076
  95. Schrezenmeier H, Marsh JC, Stromeyer P, Muller H, Heimpel H, Gordon-Smith EC, et al. A phase I/II trial of recombinant human interleukin-6 in patients with aplastic anemia. Br J Haematol. 1995;90:283–292
  96. Gordon MS, McCaskill-Stevens WJ, Battiato LA, Loewy J, Loesch D, Breeden E, et al. A phase I trial of recombinant human interleukin-11 (Neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood. 1996;87:3615–3624
  97. Tepler I, Elias L, Smith JW, Hussein M, Rosen G, Chang AY, et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood. 1996;87:3607–3614
  98. Isaacs C, Robert NJ, Bailey A, Schuster MW, Overmoyer B, Graham M, et al. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol. 1997;15:3368–3377
  99. Rowe JM, Avivi I. Clinical use of hematopoietic growth factors. In:  Hoffman R,  Benz EJ,  Shattil SJ,  Furie B,  Cohen HJ,  Silverstein LE, et al. editor. Hematology: Basic Principles and Practice. Philadephia, PA: Elsevier Churchill Livingstone; 2005;p. 1039
  100. Kaya JA. FDA licensure of NEUMEGA to prevent severe chemotherapy-induced thrombocytopenia. Stem Cells. 1998;16(suppl 2):207–223
  101. Ghalib R, Levine C, Hassan M, McCelland T, Gross J, Stribling R, et al. Recombinant human interleukin-11 improves thrombocytopenia in patients with cirrhosis. Hepatology. 2003;37:1165–1171
  102. Lawitz EJ, Hepburn MJ, Casey TJ. A pilot study of interleukin-11 in subjects with chronic hepatitis C and advanced liver disease nonresponsive to antiviral therapy. Am J Gastroenterol. 2004;99:2359–2364
  103. Kurzrock R, Cortes J, Thomas DA, Jeha S, Pilat S, Talpaz M, et al. Pilot study of low-dose interleukin-11 in patients with bone marrow failure. J Clin Oncol. 2001;19:4165–4172
  104. Montero AJ, Estrov Z, Freireich EJ, Khouri IF, Koller CA, Kurzrock R, et al. Phase II study of low-dose interleukin-11 in patients with myelodysplastic syndrome. Leuk Lymphoma. 2006;47:2049–2054
  105. Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, Broxmeyer HE, Kudelka AP, Freedman RS, et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecological cancer. Ann Intern Med. 2000;132:364–368
  106. Vadhan-Raj S, Patel S, Bueso-Ramos C, Folloder J, Papadopolous N, Burgess A, et al. Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia. J Clin Oncol. 2003;21:3158–3167
  107. Nash RA, Kurzrock R, DiPersio J, Vose J, Linker C, Maharaj D, et al. A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2000;6:25–34
  108. Wolff SN, Herzig R, Lynch J, Ericson SG, Greer JP, Stein R, et al. Recombinant human thrombopoietin (rhTPO) after autologous bone marrow transplantation: A phase I pharmacokinetic and pharmacodynamic study. Bone Marrow Transplant. 2001;27:261–268
  109. O’Malley CJ, Rasko JE, Basser RL, McGrath KM, Cebon J, Grigg AP, et al. Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation. Blood. 1996;88:3288–3298
  110. Basser RL, Rasko JEJ, Clarke K, Cebon J, Green MD, Hussein S, et al. Thrombopoietic effects of pegylated recombinant human megakaryocytic growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet. 1996;348:1279–1281
  111. Fanucchi M, Glaspy J, Crawford J, Garst J, Figlin R, Sheridan W, et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med. 1997;336:404–409
  112. Bolwell B, Vredenburgh J, Overmoyer B, Gilbert C, Chap L, Menchaca DM, et al. Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation. Bone Marrow Transplant. 2000;26:141–145
  113. Fields KK, Crump M, Bence-Bruckler I, Bernstein S, Williams S, Frankel S, et al. Use of PEG-rHuMGDF in platelet engraftment after autologous stem cell transplantation. Bone Marrow Transplant. 2000;26:1083–1088
  114. Schuster MW, Beveridge R, Frei-Lahr D, Abboud CN, Cruickshank S, Macri M, et al. The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation. Exp Hematol. 2002;30:1044–1050
  115. Schiffer CA, Miller K, Larson RA, Amrein PC, Antin JH, Zani VJ, et al. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood. 2000;95:2530–2535
  116. Archimbaud E, Ottomann OG, Yin JA, Lechner K, Dombret H, Sanz MA, et al. A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood. 1999;94:3694–3701
  117. Geissler K, Yin JA, Ganser A, Sanz MA, Szer J, Raghavachar A, et al. Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia—A randomized, placebo-controlled, double-blind safety and efficacy study. Ann Hematol. 2003;82:677–683
  118. Takedatsu H, Yoshimoto K, Okamura T, Miyazaki H, Kuwaki T, Sata M, et al. Determination of thrombopoietin-derived peptides recognized by both cellular and humoral immunities in healthy donors and patients with thrombocytopenia. Stem Cells. 2005;23:975–982
  119. Basser RL, O’Flaherty E, Green M, Edmonds M, Nichol J, Menchaca DM, et al. Development of pancytopenia with neutralizing antibodies to thrombocytopenia after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood. 2002;99:2599–2602
  120. Li J, Yang C, Xia Y, Bertino A, Glaspy J, Roberts M, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001;98:3241–3248
  121. Kajihara M, Okazaki Y, Kato S, Ishii H, Kawakami Y, Ikeda Y, et al. Evaluation of platelet kinetics in patients with liver cirrhosis:similarity to idiopathic thrombocytopenic purpura. Hapatology. 2007;22:112–118
  122. Schoffski P, Tacke F, Trautwein C, Martin MU, Caselitz M, Hecker H, et al. Thrombopoietin serum levels are elevated in patients with hepatitis B/C infection compared to other causes of chronic liver disease. Liver. 2002;22:114–120
  123. Shimodaira S, Ishida F, Ichikawa N, Tahara T, Kato T, Kodaira H, et al. Serum thrombopoietin (c-Mpl ligand) levels in patients with liver cirrhosis. Thromb Haemost. 1996;76:545–548
  124. Peck-Radosavljevic M, Wichlas M, Zacherl J, Steigler G, Stohlawetz P, Fuchsjager M, et al. Thrombopoietin induces resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production. Blood. 2000;95:795–801
  125. Peck-Radosavljevic M, Zacherl J, Wichlas M, Sims P, Meng YG, Panzer S, et al. Thrombopoietic cytokines and reversal of thrombocytopenia after liver transplantation. Eur J Gastroenterol Hepatol. 1999;11:151–156
  126. McMillan R, Nugent D. The effect of antiplatelet autoantibodies on megakaryocytopoiesis. Int J Hematol. 2005;81:94–99
  127. Bussel JB, Mukherjee R, Stone AJ. A pilot study of rhuIL-11 treatment of refractory ITP. Am J Hematol. 2001;66:172–177
  128. Nomura S, Dan K, Hotta T, Fujimura K, Ikeda Y. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood. 2002;100:728–730
  129. Kuter DJ, Goodnough LT, Romo J, DiPersio J, Peterson R, Tomita D, et al. Thrombopoietin therapy increases platelet yields in healthy platelet donors. Blood. 2001;98:1339–1345
  130. Goodnough LT, Kuter DJ, McCullough J, Slichter SJ, DiPersio J, Romo J, et al. Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin. Blood. 2001;98:1346–1351
  131. Vadhan-Raj S, Kavanagh JJ, Freedman RS, Folloder J, Currie LM, Bueso-Ramos C, et al. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomized cross-over study. Lancet. 2002;359:2145–2152
  132. Kuter DJ. New thrombopoietic growth factors. Blood. 2007;Feb 8 [Epub ahead of print]
  133. Nichol JL. AMG 531: An investigational thrombopoiesis-stimulating peptibody. Pediatr Blood Cancer. 2006;47:723–725
  134. Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetocs of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol and Ther. 2004;76:628–638
  135. Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Eng J Med. 2006;355:1672–1682
  136. Newland A, Caulier MT, Kappers-Klunne M, Schipperus MR, Lefrere F, Zwaginga JJ, et al. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol. 2006;135:547–553
  137. Kuter DJ, Bussel J, George J, Aledort L, Lichtin A, Lyons R, et al. Long-term dosing of AMG 531 in thrombocytopenic patients with immune thrombocytopenic purpura: 48-week update. Blood. 2006;108:144a;(abstr)
  138. Duffy KJ, Darcy MG, Delorme E, Dillon SB, Eppley DF, Erickson-Miller C, et al. Hydrazinonaphthalene and azonaphthalene thrombopoietin mimics are nonpeptydidyl promoters of megakaryocytopoiesis. J Med Chem. 2001;44:3730–3745
  139. Jenkins J, Nicholl R, Williams D, Baidoo C, Phillips J, Deng Y, et al. An oral, non-peptide, small molecule thrombopoietin receptor agonist increases platelet counts in healthy subjects. Blood. 2004;104:797a;(abstr)
  140. Bussel JB, Cheng G, Saleh M, Kovaleva L, Stone N, Mayer B, et al. Analysis of bleeding in patients with immune thrombocytopenic purpura (ITP): A randomized, double-blind, placebo-controlled trial of eltrombopag, an oral platelet growth factor. Blood. 2006;108:144a;(abstr)
  141. McHutchison JG, Afdhal NH, Dusheiko G, Schiffman ML, Rodriguez-Torres M, Sigal S, et al. Eltrombopag, an oral platelet growth factor, facilitates initiation of interferon therapy in subjects with HCV associated thrombocytopenia: results from a phase II placebo controlled, double-blind, dose-ranging study. Hepatology. 2006;44:692a;(abstr)
  142. Nakamura Y, Miyakawa Y, Miyamura A, Yamane A, Suzuki H, Ito M, et al. A novel nonpeptidyl human c-Mpl activator stimulates human megakaryopoiesis and thrombosis. Blood. 2006;107:4300–4307
  143. Yamane A, Nakamura T, Ito M, Ohnishi Y, Ikeda Y, Miyakawa Y. Prevention of human interferon-alpha-induced thrombocytopenia by a non-petidyl human thrombopoietin receptor activator, NIP-004. Blood. 2006;108:339a;(abstr 1145)
  144. Desjardins RE, Tempel DL, Lucek R, Kuter DJ. Single and multiple oral doses of AKR-501 (YM477) increase the platelet count in healthy volunteers. Blood. 2006;108:145a;(abstr 477)
  145. Frederickson S, Renshaw MW, Lin B, Smith LM, Calveley P, Springhorn JP, et al. A rationally designed agonist antibody fragment that functionally mimics thrombopoietin. Proc Natl Acad Sci U S A. 2006;103:14307–14312
  146. Orita T, Tsunoda H, Yabuta N, Nakano K, Yoshino T, Hirata Y, et al. A novel approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor. Blood. 2005;105:562–566
  147. Rinehart J, Hersh E, Issell B, Triozzi P, Buhles W, Neidhart J, et al. Phase 1 trial of recombinant human interleukin-1 beta (rhIL-1 beta), carboplatin, and etoposide in patients with solid cancers: Southwest Oncology, Group Study 8940. Cancer Invest. 1997;15:403–410
  148. Speyer JL, Mandeli J, Hochster H, Runowicz C, Wadler S, Wallach R, et al. A phase I trial of cyclophosphamide and carboplatinum combined with interleukin-3 in women with advanced-stage ovarian cancer. Gynecol Oncol. 1995;56:387–394
  149. O’Shaughnessy JA, Venzon DJ, Gossard M, Noone MH, Denicoff A, Tolcher A, et al. A phase I study of sequential versus concurrent interleukin-3 and granulocte-macrophage colony-stimulating factor in advanced breast cancer patients treated with FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy. Blood. 1995;86:2913–2921
  150. Palmieri S, Leonardi V, Danova M, Porta C, Ferrari S, Fincato G, et al. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients. Haematologica. 1999;84:1016
  151. Taylor DS, Lee Y, Sieff CA, Homans A, Garrison L, Guinan EC, et al. Phase I/II trial of PIXY321 (granulocyte-macrophage colony stimulating factor/interleukin-3 fusion protein) for treatment of inherited and acquired marrow failure syndromes. Br J Haematol. 1998;103:304–307
  152. Vose JM, Pandite AN, Beveridge RA, Geller RB, Schuster MW, Anderson JE, et al. Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein versus granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for non-Hodgkin’s lymphoma: Results of a randomized double-blind trial. J Clin Oncol. 1997;15:1617–1623
  153. D’Hondt V, Humblet Y, Guillaume T, Baatout S, Chatelain C, Berliere M, et al. Thrombopoietic effects and toxicity of interleukin-6 in patients with ovarian cancer before and after chemotherapy: A multicentric placebo-controlled, randomized phase Ib study. Blood. 1995;85:2347–2353
  154. Veldhuis GJ, Willemse PH, Sleijfer DT, van der Graaf WT, Groen HJ, Limburg PC, et al. Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non-small-cell lung cancer. J Clin Oncol. 1995;13:2585–2593
  155. Hochster H, Speyer JL, Mandeli JP, Runowicz C, Wadler S, Berk G, et al. A phase II double-blind randomized study of the simultaneous adminstration of recombinant human interleukin-6 and recombinant human granulocyte colony-stimulating factor following paclitaxel and carboplatin chemotherapy in patients with advanced epithelial ovarian cancer. Gynecol Oncol. 1999;72:292–297
  156. Vredenburgh JJ, Hussein A, Fisher D, Hoffman M, Elkordy M, Rubin P, et al. A randomized trial of recombinant human interleukin-11 following autologous bone marrow transplantation with peripheral blood progenitor cell support in patients with breast cancer. Biol Blood Marrow Transplant. 1998;4:134–141
  157. Bussel JB, Mukherjee R, Stone AJ. A pilot study of rhuIL-11 treatment of refractory ITP. Am J Hematol. 2001;66:172–177
  158. Cairo MS, Davenport V, Bessmertny O, Goldman SC, Berg SL, Kreissman SG, et al. Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: A clinical, haematological and biological study. Br J Haematol. 2005;128:49–58
  159. Basser RL, Rasko JE, Clarke K, Cebon J, Green MD, Grigg AP, et al. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood. 1997;89:3118–3128
  160. Basser RL, Underhill C, Davis I, Green MD, Cebon J, Zalcberg J, et al. Enhancement of platelet recovery after myelosupressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer. J Clin Oncol. 2000;18:2852–2861

 Supported in part by a grant from National Cancer Institute 1P01CA108671 (R.H.), the Department of Defense MP048010 (R.H.), and by the Myeloproliferative Disorders Foundation (R.H.)

PII: S0037-1963(07)00068-6

doi: 10.1053/j.seminhematol.2007.04.005

Seminars in Hematology
Volume 44, Issue 3 , Pages 166-182 , July 2007

Article Tools

* Image Usage & Resolution